drugset / Trial / NCT01726335

Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia

NCT01726335

Phase 4 Completed 53 enrolled Janssen-Cilag Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate efficacy, safety and tolerance of long-acting risperidone when switching from oral antipsychotics in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).

Timeline

Start
2006-01
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 25 mg Intramuscular

Indications